Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Gene IDH1
Variant R132H
Impact List missense
Protein Effect gain of function
Gene Variant Descriptions IDH1 R132H lies within the active site of the Idh1 protein (PMID: 19228619). R132H results in decreased conversion of isocitrate to alpha-ketoglutarate by Idh1, but also confers a gain of function to Idh1, as indicated by increased conversion of alpha-ketoglutarate to the onco-metabolite 2HG (R(-)-2-hydroxyglutarate) in cell culture and in vitro assays, and is associated with increased 2HG levels in patient samples (PMID: 19935646, PMID: 23731180).
Associated Drug Resistance
Category Variants Paths

IDH1 mutant IDH1 act mut IDH1 R132H

IDH1 mutant IDH1 R132X IDH1 R132H

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005896.4
gDNA chr2:g.208248388C>T
cDNA c.395G>A
Protein p.R132H
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_005896 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_005896.3 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_001282386.1 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_001282387.1 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_001282386.1 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_001282387.1 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_001282386 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_001282387 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38
NM_005896.4 chr2:g.208248388C>T c.395G>A p.R132H RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02193347 Phase I Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST) Completed USA 0
NCT05303519 Phase II DS-1001b Safusidenib Phase 2 Study in IDH1 Mutant Glioma Recruiting USA 0
NCT04088188 Phase I Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Terminated USA 0
NCT04164901 Phase III Vorasidenib Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) Active, not recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN 3
NCT03970447 Phase II Lomustine Regorafenib Temozolomide A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) Recruiting USA | FRA | DEU | CAN | AUS 1
NCT05484622 Phase I Vorasidenib Pembrolizumab + Vorasidenib Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma Recruiting USA 0
NCT02525692 Phase II ONC201 Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma Active, not recruiting USA 0
NCT05876754 Phase III Ivosidenib An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe) Recruiting NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT | AUS 1
NCT03224104 Phase I Radiotherapy + Zotiraciclib Temozolomide + Zotiraciclib Zotiraciclib Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) Completed NLD | FRA | DEU | AUT 1
NCT04056910 Phase II Ivosidenib + Nivolumab Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors Completed USA 0
NCT05921760 Phase Ib/II Ipilimumab + Ivosidenib + Nivolumab Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma Recruiting USA | GBR 0
NCT03343197 Phase I Ivosidenib Vorasidenib Study of AG-120 and AG-881 in Subjects With Low Grade Glioma Active, not recruiting USA 0
NCT03893903 Phase I Avelumab IDH1 R132H peptide vaccine Avelumab + IDH1 R132H peptide vaccine AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC) Recruiting DEU 0
NCT03953898 Phase II Olaparib Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Active, not recruiting USA 0
NCT05609994 Phase I PEPIDH1M vaccine + Vorasidenib ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy) Not yet recruiting USA 0
NCT02977780 Phase II CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) Recruiting USA 0
NCT06161974 Phase II Olutasidenib + Temozolomide Study of Olutasidenib and Temozolomide in HGG Not yet recruiting USA | NLD | GBR | DEU | CAN | AUS 0